Sources: AstraZeneca, Bristol make bids for Amylin

Count AstraZeneca ($AZN) and Bristol-Myers Squibb ($BMY) among the bidders for diabetes drugmaker Amylin Pharmaceuticals ($AMLN), sources tell Reuters. Bristol got the bidding on Amylin started with a rebuffed offer earlier this spring, and AstraZeneca has been in the conversation about potential Amylin buyers in part because of the London-based drugmaker's acute need for new products and interest in the growing diabetes market. The two companies join Sanofi ($SNY) and Merck ($MRK) among initial bidders for Amylin, whose investors such as activist Carl Icahn would likely celebrate a bidding war among the Big Pharma groups. Article

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.